LifeSci Capital
VC Fund
New York, United States
LifeSci Capital is a research-driven investment bank company.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries LifeSci Capital invests in
Stages LifeSci Capital invests in
Countries LifeSci Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Evertts
|
|||
Hany Awadalla
|
|||
Investment Focus
Industry
- Biotechnology 2 (100%)
- Medical Device 2 (100%)
- Medical 1 (50%)
- Software 1 (50%)
- Biopharma 1 (50%)
Stage
- Series C 1 (50%)
- Post-IPO Equity 1 (50%)
Country
- Israel 1 (50%)
- United Kingdom 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Adam Evertts
Senior Research Analyst
|
Senior Research Analyst | Total investments: 0 | Find email | |
|
Hany Awadalla
Managing Director and Head of Investment Banking
|
Managing Director and Head of Investment Banking | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M / Series C / Mar 18, 2025 | |
InspireMD
|
InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard.The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission is to utilize its proprietary technology tomake its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: embolic showers, restenosis, and late stent thrombosis.InspireMD intends to pursue applications of its innovative technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. | $113.6M / Post-IPO Equity / May 15, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does LifeSci Capital invest in?
LifeSci Capital invests primarily in Biotechnology, Medical Device and Medical startups, most often at Series C and Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact LifeSci Capital?
Public channels for LifeSci Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LifeSci Capital?
The team at LifeSci Capital includes Adam Evertts (Senior Research Analyst) and Hany Awadalla (Managing Director and Head of Investment Banking). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
